WALTHAM, Mass.--(BUSINESS WIRE)--Deciphera Pharmaceuticals, a clinical-stage biotechnology company focused on developing advanced kinase inhibitor treatments targeting the tumor cell and the tumor microenvironment, today announced that an abstract highlighting the company’s highly-selective small molecule CSF1R inhibitor, DCC-3014, has been selected for presentation at the American Association for Cancer Research Annual Meeting 2016, taking place April 16-20, 2016 in New Orleans. DCC-3014 was designed as a highly-specific macrophage immunomodulatory agent based on the company’s Switch Control Inhibitor platform. In preclinical cancer models, DCC-3014 was shown to significantly enhance anti-tumor activity when used in combination with an anti-PD-1 checkpoint inhibitor. Deciphera expects to initiate a Phase 1 clinical trial of DCC-3014 in the second half of 2016.
